Cargando…
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab (Uplizna(®)) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive. Inebilizumab targets the B cell antigen CD19 and effectively depletes circulating B cells, thus suppressin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550749/ https://www.ncbi.nlm.nih.gov/pubmed/36070074 http://dx.doi.org/10.1007/s40263-022-00949-7 |